RVL Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• RVL-1201 · Ophthalmology
  RVL-1201 is an alpha-1A adrenergic agonist that increases pupil dilation (mydriasis) by stimulating alpha-1A receptors on the dilator pupillae muscle.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• RVL Pharmaceuticals, Inc. portfolio CI brief
• RVL Pharmaceuticals, Inc. pipeline updates RSS